期刊文献+

聚己内酯微球在“双S”注射技术中的具体应用及疗效观察 被引量:4

The Specific Application of Polycaprolactone Microspheres in the"Double S"Injection Technique and Its Therapeutic Effect
在线阅读 下载PDF
导出
摘要 目的探查聚己内酯微球在“双S”注射技术中的具体应用及其安全性和有效性。方法选择面中部存在凹陷或下垂的女性30例,利用注射用聚己内酯面部填充剂(ELLANSÉ®)进行“双S”点位注射。分别于注射后3天、1周、1个月、3个月、6个月进行复查记录皱纹严重程度分级(WSRS)评价、全局美学改善量表(GAIS)分级评价、满意度评价、不良反应评价。结果皱纹严重程度分级(WSRS)评价:受试者及研究者认为治疗后即刻,皱纹(WSRS)及全全局美学改善量表(GAIS)的改善最为凸显,满意度最高。术后1-3个月时皱纹及全局美容效果的改善情况及满意度均有所下降,6个月时改善效果及满意度提升。不良反应评价:发生的近期不良反应包括红斑、水肿、淤青、胀痛、不平整等均在1周左右基本缓解及消退,均在受试者接受范围内,属于正常反应。未见其他明显近期和远期不良反应发生。结论注射用聚己内酯(ELLANSÉ®)行“双S”方案注射能有效安全的改善亚洲人面中部凹陷、松垂等问题。 Objective To investigate the specific application,safety and effectiveness of polycaprolactone microspheres in"Double S"injection technology.Methods A total of 30 female beauty seekers with depression or droop in the middle of the face were selected,and the"Double S"point injection was conducted with the face filler of polycaprolactone for injection(ELLANSÉ®).On the 3rd day,1st week,1st month,3rd month and 6th month after injection,the wrinkle severity rating(WSRS),global cosmetic effect rating(GAIS),satisfaction rating and adverse reaction rating were reviewed and recorded.Results Wrinkle Severity Rating(WSRS)evaluation:The subjects and researchers believed that the improvement of wrinkles(WSRS)and global cosmetic effect rating(GAIS)was the most prominent and the satisfaction was the highest immediately after treatment.The improvement and satisfaction of wrinkles and overall beauty effect decreased from 1 to 3 months after surgery,and improved at 6 months.Evaluation of adverse reactions:the recent adverse reactions including erythema,edema,bruising,distension and pain,and unevenness were basically relieved and subsided in about one week,which were within the acceptance range of the subject and belonged to normal reactions.No other obvious shortterm and long-term adverse reactions occurred.Conclusions Polycaprolactone for injection(ELLANSÉ®)can effectively and safely improve the sagging and sagging of the middle face in Asians with"Double S"regimen.
作者 尹敏 殷珊 刘翔 吴姗姗 何加炜 周欢 周佳 YIN Min;YIN Shan;LIU Xiang;WU Shan-shan;HE Jia-wei;ZHOU Huan;ZHOU Jia(Mylike Cosmetic Hospital,Hunan Province,410007,China)
出处 《中国医疗美容》 2022年第11期14-20,共7页 China Medical Cosmetology
关键词 聚己内酯微球 “双S”注射 亚洲人 衰老 面部骨性结构缺陷 Polycaprolactone microspheres,"Double S"injection,Asian,Aging Bone structure defect of face
  • 相关文献

参考文献4

二级参考文献13

  • 1Kogan G, Solt6s L, Stern R, et al. Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications[J]. Biotechnol Lett, 2007, 29(1): 17-25.
  • 2Chong BF, Blank LM, McLaughlin IL et al. Microbial Hyaluronic acid production[J]. Appl Microbiol Biotechnol, 2005, 66(4): 341-351.
  • 3Kanchwala SK, Holloway L, Bucky LP. Reliable Soft tissue augmentation: a clinical comparison of injectable soft-tissue fillers for facial-volume augmentation[J]. Ann Plast Surg, 2005, 55(1): 30-35.
  • 4Laurent TC. The chemistry, biology and medical applications of hyaluronan and its derivatives[M]. London: Portland Press, 1998: 267-281.
  • 5Balazs EA, Denlinger JL. Clinical uses of hyaluronan[J]. Ciba Found Syrup, 1989, 143: 265-275.
  • 6国家食品药品监督管理局.《医疗器械监督管理条例》(闰务院令第276号)[EB/OL]. (2000-01-04)[2012-07-30]. http://www.sda. gov.cn/WS01/CL0784/16570.html.
  • 7国家食品药品监督管理局.关于医朋透明质酸钠产品管理类别的公告(闽家食品药品监督管理局公告2009年第8l号)[EB/OL]. (2009-12-24)[2012-07-30]. http://www.sda.gov.cn/WSO 1 / CLOO87/44748.html.
  • 8国家食品药品监督管理局.医疗器械分类规则(硒令第15号)[EB/OL](2000-04-05)[20l2-07-301.http://www.sda.gov,cn/WSO1/CL0053/24454.hlml_.
  • 9国家食品药品监督管理局.《医疗器械注册管理办法》(硒令第l6号)(EB/OL].(2004-08-09)[2012-07-301.http://www.sda.gov.cn/WSOl/CL0053/25844.html.
  • 10国家食晶药品监督管理局.《医疗器械临床试验规定》(局令第5号)[EB/OL].(2004-01-17)[2012-07-30].http://www.sda.gov.cn/WS0l/CL0053/24475.html.

共引文献39

同被引文献44

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部